Baricitinib – Medxy AI

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial

By MedXY 03/05/2026

A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both treatments showing favorable safety profiles.

Dermatology news Pediatrics

Unorthodox JAK Inhibitor Dosing in Pediatric Moderate-to-Severe Alopecia Areata: A Comparative Evaluation of Tofacitinib and Baricitinib

By MedXY 03/05/2026

This study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.

news Pediatrics Rheumatology

Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial

By MedXY 01/13/2026

A post-hoc analysis of the Phase 3 JUVE-BASIS trial identifies key serum biomarkers, including CCL7, CCL18, and IL-6, that correlate with clinical response to baricitinib in JIA, suggesting potential pathways for personalized JAK inhibitor therapy.

Dermatology Pediatrics

Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial

By MedXY 10/24/2025

The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases after one year of treatment.